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Selenium (Se) is an essential trace element with a wide
spectrum of biological activity and as a potential antic-
ancer agent, it has gained a lot of scientific attention.
Since the first hypothesis concerning chemopreventive
properties of selenium was formulated (in 1969), numer-
ous studies on Se and cancer, including human rando-
mized controlled trials, have been conducted. Whereas
studies in vivo indicated that Se supplementation pro-
tected animals from chemically or biologically induced
cancer, epidemiological studies generated contradictory
data, and it seems that the relationship between sele-
nium and cancer prevention in humans is complex. In
the light of recent epidemiological data suggesting that
long term supplementation with Se does not prevent
prostate cancer in men and may increase the risk of dia-
betes in individuals with high selenium status, the use of
Se in terms of cancer prevention is not recommended
for the general population. It is considered that the ben-
eficial effects of Se are probably limited only to the
undernourished populations and they are strictly related
to dose (in a U-shaped manner) and the chemical form
of this trace element.
Functions of Se in human organism are mainly asso-
ciated with the presence of selenoproteins. These are
proteins containing Se in the form of selenocysteine
(Sec), the 21st amino acid, which due to its own codon in
mRNA, is incorporated into the polypeptide chain during
protein biosynthesis. So far more than 25 human seleno-
proteins have been identified, including those with
important enzymatic activity (glutathione peroxidases,
thioredoxin reductases and iodothyronindeiodinases).
Notably, functions of some selenoproteins are still not
recognized. It has been recently shown that polymorphic
variants of selenoprotein encoding genes are associated
with the altered cancer risk at different sites (lung, pros-
tate, colon, breast, and bladder). Such associations have
already been found for genetic polymorphism of cytosolic
glutathione peroxidase (GPx1), phospholipid glutathione
peroxidase (GPx4), 15 kDaselenoprotein (Sep15), thiore-
doxin reductase 1 (TrxR1) and selenoprotein P (Sepp1).
Our study also indicated that genetic polymorphism of
Sep15 modified the risk of lung cancer in the interaction
with selenium status. Similar type of interactions was
observed recently by other authors in prostate cancer
individuals, in which the risk was modified by Se status
and genetic polymorphisms of three selenoproteins: SelK,
TrxR1 and TrxR2. These two studies (on lung and pros-
tate cancer) indicate that genetic susceptibility associated
with polymorphic variants of selenoprotein encoding
genes, may be another, apart from dose a chemical form,
factor that affects biological activity of selenium in
humans.
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